总时间（秒）：9565.83
问答时间（秒）：638.31

```json
{
  "functional_evidence_assessment": []
}
```
Based on the provided text, there is no explicit functional evidence details about gene variants that would allow application of the ACMG functional evidence evaluation flowchart. The text fragment contains information about genetic analysis methods (MALDI-TOF mass spectrometry) and study design elements (case-control study with sporadic PD cases and controls), but it does not provide specific functional data about the Gly2385Arg variant or other LRRK2 mutations mentioned in the context.
```

The text fragment does not contain the necessary information about functional assays, experimental controls, statistical analyses or OddsPath calculations that would be required to apply the ACMG functional evidence evaluation flowchart. While the Gly2385Arg variant is mentioned as being associated with increased risk, no functional evidence is provided in the text fragment that would allow assessment of its pathogenicity using the ACMG criteria.
```

```json
{
  "functional_evidence_assessment": []
}
``` Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```

Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```
Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```
Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```
Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```
Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```
Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```
Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```
Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```
Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```
Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```
Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```
Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```

Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant according to ACMG criteria. The appropriate response is to indicate that there is insufficient information to make an assessment.
```json
{
  "functional_evidence_assessment": []
}
```


Based on the provided text fragment, there is insufficient information to perform a complete ACMG functional evidence evaluation for any variants. The text mentions the Gly2385Arg variant in LRRK2 and describes some study design elements, but it does not provide specific functional data, assay methods, controls, replicates, or statistical analyses that would be necessary to apply the ACMG functional evidence evaluation flowchart.

The text appears to be a fragment from the methods section of a genetic association study, mentioning:

1. The Gly2385Arg variant in LRRK2
2. A case-control study design with Parkinson's disease (PD) cases and controls
3. Screening for LRRK2 mutations
4. DNA extraction and MALDI-TOF mass spectrometry as a genotyping method

However, it does not provide:
- Any functional assay results for this variant
- Details about how the variant's function was tested
- Information about experimental controls
- Statistical analyses related to functional impact
- OddsPath calculations

Without this information, it's not possible to determine the strength of functional evidence for this variant